register

News & Trends - Pharmaceuticals

First long-acting reversible contraceptive listed on the PBS since 2003

Health Industry Hub | March 2, 2020 |

Pharma News: The first long-acting reversible contraceptive to be added to the Pharmaceutical Benefits Scheme (PBS) in more than 15 years comes as a timely boost to Federal Government efforts to increase availability and uptake of longer-term birth control options.

Bayer Australia welcomed Federal Health Minister Greg Hunt’s announcement that Kyleena will receive a government subsidy from 1 March – allowing women to pay just $41.00 (general patients) or $6.60 (concession card holders) for a device that provides up to five years of contraception.

The Kyleena Intrauterine Device (IUD) is a small, flexible T-shaped device inserted into a woman’s uterus by a healthcare professional. It releases a low dose of progestin hormone to prevent pregnancy. The device can be removed by a healthcare provider at any time, allowing fertility to return.

“The PBS listing of Kyleena provides women with an important new birth control option that works to prevent pregnancy for up to five years,” said Dr Eduardo Pimenta, Country Medical Director from Bayer ANZ.

“Improved access to long-acting reversible contraception has become a health policy priority in Australia as it offers continuous, reliable contraception that’s not contingent on user behaviour.”

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture measure up in the industry, according to results from employee feedback? Get the benchmark analysis by contacting us.

“A recent survey of more than 1,000 women who use oral contraception found that 90 per cent had forgotten to take their pill at least once,” he said.

Dr Pimenta congratulated Minister Hunt on the Federal Government’s commitment to women’s health and noted that the National Women’s Health Strategy 2020-2030 identifies increased access to long-acting reversible contraception as a key measure of success.

LARCs (implants or intrauterine devices (IUDs) are the most effective way of preventing unintended pregnancies, but just 11 per cent of Australian women currently use them.

A recent study conducted by researchers at Monash University’s SPHERE NHMRC Centre for Excellence in Women’s Sexual and Reproductive Health in Primary Care found that when GPs were provided with training in effectiveness-based contraceptive counselling and a portal to directly book an insertion procedure in a LARC insertion clinic, there was a significant increase in LARC uptake.

Lead researcher and Director of SPHERE, Professor Danielle Mazza, said many national and international bodies recommended the use of LARCs because they were the most effective form of contraception.  

Research published in the Medical Journal of Australia relating to a study of 2,013 Australian women found that 1,390 women had been pregnant in the last ten-years, with 26% of these pregnancies being unintended. The study found that approximately 30% of these unintended pregnancies were terminated.

Because Kyleena slowly releases a progestogen hormone called levonorgestrel into the woman’s uterus, only small amounts of the hormone enter the blood. For the first 3-6 months, periods may become irregular and the number of bleeding days may increase. Over this period, women may also have frequent spotting or light bleeding. Some women have heavy bleeding during this time. However, after using Kyleena for a while, the number of bleeding and spotting days is likely to lessen. For some women, periods will stop altogether. When Kyleena is removed, menstrual periods should return.

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.